Open Access

TFF3 and TFF1 expression levels are elevated in colorectal cancer and promote the malignant behavior of colon cancer by activating the EMT process

  • Authors:
    • Aikeremu Yusufu
    • Paerhati Shayimu
    • Rousidan Tuerdi
    • Cheng Fang
    • Fei Wang
    • Haijiang Wang
  • View Affiliations

  • Published online on: August 5, 2019     https://doi.org/10.3892/ijo.2019.4854
  • Pages: 789-804
  • Copyright: © Yusufu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Reports on the roles of the secreted trefoil factor (TFF)1 and 3 in colorectal cancer (CRC) and their underlying mechanisms of action in tumorigenesis are not common and are controversial. In the present study, the mRNA expression and promoter methylation of TFF1 and TFF3 in cancer and adjacent normal tissues were investigated, and their association with other clinical factors and patient prognosis were evaluated. Moreover, the association between TFF3 and epithelial‑mesenchymal transition (EMT) was explored by overexpressing or inhibiting TFF3 expression. The results revealed that the mRNA level of TFF1 and TFF3 in the cancer tissues was significantly higher than that in the matched adjacent normal tissues (P=0.034 and P=0.007, respectively), and a higher expression of TFF3, but not TFF1, was predominantly associated with clinicopathological factors and a poorer prognosis. No correlation was observed between promoter methylation and the expression of TFF1 or TFF3. The overexpression of TFF3 promoted the proliferation, migration and invasiveness of HT29 cells, and induced an increase in the expression of Twist1, Snail and Vimentin, while causing a decrease in E‑cadherin expression. On the contrary, the knockdown of TFF3 resulted in opposite effects in the LoVo cells. On the whole, the findings of this study indicate that TFF3 may be a promising new factor for the estimation of the survival of patients with CRC, and may promote the malignant progression of CRC by activating the EMT process. Therefore, TFF3 may be a future potential therapeutic target for CRC.

References

1 

Cai SJ and Peng JJ: Colorectal cancer epidemiology and prevention strategies. In: Proc Academic Annual Conference of CSCO 2014; pp. 294–301. Peking, China. 2014

2 

Li S, Wang J, Lu Y and Fan D: Screening and early diagnosis of colorectal cancer in China: A 12 year retrospect (1994 2006). J Cancer Res Clin Oncol. 133:679–686. 2007. View Article : Google Scholar : PubMed/NCBI

3 

Gespach C: Trefoil factors. Encyclopedia of Cancer. Schwab M: Springer; Berlin, Heidelberg: pp. 4652–4658. 2011

4 

Sands BE and Podolsky DK: The trefoil peptide family. Annu Rev Physiol. 58:253–273. 1996. View Article : Google Scholar : PubMed/NCBI

5 

Wright NA, Poulsom R, Stamp G, Van Noorden S, Sarraf C, Elia G, Ahnen D, Jeffery R, Longcroft J, Pike C, et al: Trefoil peptide gene expression in gastrointestinal epithelial cells in inflammatory bowel disease. Gastroenterology. 104:12–20. 1993. View Article : Google Scholar : PubMed/NCBI

6 

Regalo G, Wright NA and Machado JC: Trefoil factors: From ulceration to neoplasia. Cell Mol Life Sci. 62:2910–2915. 2005. View Article : Google Scholar : PubMed/NCBI

7 

Hernández C, Santamatilde E, McCreath KJ, Cervera AM, Díez I, Ortiz Masiá D, Martínez N, Calatayud S, Esplugues JV and Barrachina MD: Induction of trefoil factor (TFF)1, TFF2 and TFF3 by hypoxia is mediated by hypoxia inducible factor 1: Implications for gastric mucosal healing. Br J Pharmacol. 156:262–272. 2009. View Article : Google Scholar

8 

Taupin D and Podolsky DK: Trefoil factors: Initiators of mucosal healing. Nat Rev Mol Cell Biol. 4:7217322003. View Article : Google Scholar : PubMed/NCBI

9 

May FE and Westley BR: Trefoil proteins: Their role in normal and malignant cells. J Pathol. 183:4–7. 1997. View Article : Google Scholar : PubMed/NCBI

10 

Prest SJ, May FE and Westley BR: The estrogen-regulated protein, TFF1, stimulates migration of human breast cancer cells. FASEB J. 16:592–594. 2002. View Article : Google Scholar : PubMed/NCBI

11 

Machado JC, Nogueira AM, Carneiro F, Reis CA and Sobrinho-Simões M: Gastric carcinoma exhibits distinct types of cell differentiation: An immunohistochemical study of trefoil peptides (TFF1 and TFF2) and mucins (MUC1, MUC2, MUC5AC, and MUC6). J Pathol. 190:437–443. 2000. View Article : Google Scholar : PubMed/NCBI

12 

Dhar DK, Wang TC, Tabara H, Tonomoto Y, Maruyama R, Tachibana M, Kubota H and Nagasue N: Expression of trefoil factor family members correlates with patient prognosis and neoangiogenesis. Clin Cancer Res. 11:6472–6478. 2005. View Article : Google Scholar : PubMed/NCBI

13 

Madsen J, Nielsen O, Tornøe I, Thim L and Holmskov U: Tissue localization of human trefoil factors 1, 2, and 3. J Histochem Cytochem. 55:505–513. 2007. View Article : Google Scholar : PubMed/NCBI

14 

Rodrigues S, Rodrigue CM, Attoub S, Fléjou JF, Bruyneel E, Bracke M, Emami S and Gespach C: Induction of the adenoma carcinoma progression and Cdc25A-B phosphatases by the trefoil factor TFF1 in human colon epithelial cells. Oncogene. 25:6628–6636. 2006. View Article : Google Scholar : PubMed/NCBI

15 

Arumugam T, Brandt W, Ramachandran V, Moore TT, Wang H, May FE, Westley BR, Hwang RF and Logsdon CD: Trefoil factor 1 stimulates both pancreatic cancer and stellate cells and increases metastasis. Pancreas. 40:815–822. 2011. View Article : Google Scholar : PubMed/NCBI

16 

Zhao S, Ma Y and Huang X: Trefoil factor 1 elevates the malignant phenotype of mucinous ovarian cancer cell through Wnt/β catenin signaling. Int J Clin Exp Pathol. 8:10412–10419. 2015.

17 

Kannan N, Kang J, Kong X, Tang J, Perry JK, Mohankumar KM, Miller LD, Liu ET, Mertani HC, Zhu T, et al: Trefoil factor 3 is oncogenic and mediates anti-estrogen resistance in human mammary carcinoma. Neoplasia. 12:1041–1053. 2010. View Article : Google Scholar : PubMed/NCBI

18 

Gu J, Zheng L, Zhang L, Chen S, Zhu M, Li X and Wang Y: TFF3 and HER2 expression and their correlation with survival in gastric cancer. Tumour Biol. 36:3001–3007. 2015. View Article : Google Scholar

19 

Pandey V, Wu ZS, Zhang M, Li R, Zhang J, Zhu T and Lobie PE: Trefoil factor 3 promotes metastatic seeding and predicts poor survival outcome of patients with mammary carcinoma. Breast Cancer Res. 16:429–448. 2014. View Article : Google Scholar : PubMed/NCBI

20 

Ishibashi Y, Ohtsu H, Ikemura M, Kikuchi Y, Niwa T, Nishioka K, Uchida Y, Miura H, Aikou S, Gunji T, et al: Serum TFF1 and TFF3 but not TFF2 are higher in women with breast cancer than in women without breast cancer. Sci Rep. 7:4846–4854. 2017. View Article : Google Scholar : PubMed/NCBI

21 

Lacroix M: Significance, detection and markers of disseminated breast cancer cells. Endocr Relat Cancer. 13:1033–1067. 2006. View Article : Google Scholar : PubMed/NCBI

22 

Im S, Yoo C, Jung JH, Choi HJ, Yoo J and Kang CS: Reduced expression of TFF1 and increased expression of TFF3 in gastric cancer: Correlation with clinicopathological parameters and prognosis. Int J Med Sci. 10:133–140. 2013. View Article : Google Scholar : PubMed/NCBI

23 

Vestergaard EM, Borre M, Poulsen SS, Nexø E and Tørring N: Plasma levels of trefoil factors are increased in patients with advanced prostate cancer. Clin Cancer Res. 12:807–812. 2006. View Article : Google Scholar : PubMed/NCBI

24 

Casado E, Garcia VM, Sánchez JJ, Gómez Del Pulgar MT, Feliu J, Maurel J, Castelo B, Moreno Rubio J, López RA, García-Cabezas MÁ, et al: Upregulation of trefoil factor 3 (TFF3) after rectal cancer chemoradiotherapy is an adverse prognostic factor and a potential therapeutic target. Int J Radiat Oncol Biol Phys. 84:1151–1158. 2012. View Article : Google Scholar : PubMed/NCBI

25 

Martin TA, Goyal A, Watkins G and Jiang WG: Expression of the transcription factors snail, slug, and twist and their clinical significance in human breast cancer. Ann Surg Oncol. 12:488–496. 2005. View Article : Google Scholar : PubMed/NCBI

26 

Khan MA, Chen HC, Zhang D and Fu J: Twist: A molecular target in cancer therapeutics. Tumour Biol. 34:2497–2506. 2013. View Article : Google Scholar : PubMed/NCBI

27 

Hu P, Yang J, Hou Y, Zhang H, Zeng Z, Zhao L, Yu T, Tang X, Tu G, Cui X, et al: lncRNA expression signatures of twist induced epithelial to mesenchymal transition in MCF10A cells. Cell Signal. 26:83–93. 2014. View Article : Google Scholar

28 

Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Δ Δ C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar

29 

Camp RL, Dolled-Filhart M and Rimm DL: X-tile: A new bio informatics tool for biomarker assessment and outcome based cut point optimization. Clin Cancer Res. 10:7252–7259. 2004. View Article : Google Scholar : PubMed/NCBI

30 

May FE: The potential of trefoil proteins as biomarkers in human cancer. Biomarkers Med. 6:301–304. 2012. View Article : Google Scholar

31 

Xiao P, Ling H, Lan G, Liu J, Hu H and Yang R: Trefoil factors: gastrointestinal specific proteins associated with gastric cancer. Clin Chim Acta. 450:127–134. 2015. View Article : Google Scholar : PubMed/NCBI

32 

Qu Y, Yang Y, Ma D and Xiao W: Increased trefoil factor 3 levels in the serum of patients with three major histological subtypes of lung cancer. Oncol Rep. 27:1277–1283. 2012. View Article : Google Scholar : PubMed/NCBI

33 

Meng JR, Tang HZ, Zhou KZ, Shen WH and Guo HY: TFF3 and survivin expressions associate with a lower survival rate in gastric cancer. Clin Exp Med. 13:297–303. 2013. View Article : Google Scholar

34 

May FE and Westley BR: TFF3 is a valuable predictive biomarker of endocrine response in metastatic breast cancer. Endocr Relat Cancer. 22:465–479. 2015. View Article : Google Scholar : PubMed/NCBI

35 

Elnagdy MH, Farouk O, Seleem AK and Nada HA: TFF1 and TFF3 mRNAs are hgher in blood from breast cancer patients with metastatic disease than those without. J Oncol. 2018:47934982018. View Article : Google Scholar

36 

Terris B, Blaveri E, Crnogorac-Jurcevic T, Jones M, Missiaglia E, Ruszniewski P, Sauvanet A and Lemoine NR: Characterization of gene expression profiles in intraductal papillary-mucinous tumors of the pancreas. Am J Pathol. 160:1745–1754. 2002. View Article : Google Scholar : PubMed/NCBI

37 

Faith DA, Isaacs WB, Morgan JD, Fedor HL, Hicks JL, Mangold LA, Walsh PC, Partin AW, Platz EA, Luo J, et al: Trefoil factor 3 overexpression in prostatic carcinoma: Prognostic importance using tissue microarrays. Prostate. 61:215–227. 2004. View Article : Google Scholar : PubMed/NCBI

38 

Huang YG, Li YF, Wang LP and Zhang Y: Aberrant expression of trefoil factor 3 is associated with colorectal carcinoma metastasis. J Cancer Res Ther. 9:376–380. 2013. View Article : Google Scholar : PubMed/NCBI

39 

Yusup A, Huji B, Fang C, Wang F, Dadihan T, Wang HJ and Upur H: Expression of trefoil factors and TWIST1 in colorectal cancer and their correlation with metastatic potential and prognosis. World J Gastroenterol. 23:110–120. 2017. View Article : Google Scholar : PubMed/NCBI

40 

Lao VV and Grady WM: Epigenetics and colorectal cancer. Nat Rev Gastroenterol Hepatol. 8:686–700. 2011. View Article : Google Scholar : PubMed/NCBI

41 

Feinberg AP: The epigenetics of cancer etiology. Semin Cancer Biol. 14:427–432. 2004. View Article : Google Scholar : PubMed/NCBI

42 

Suzuki K, Suzuki I, Leodolter A, Alonso S, Horiuchi S, Yamashita K and Perucho M: Global DNA demethylation in gastrointestinal cancer is age dependent and precedes genomic damage. Cancer Cell. 9:199–207. 2006. View Article : Google Scholar : PubMed/NCBI

43 

Okada H, Kimura MT, Tan D, Fujiwara K, Igarashi J, Makuuchi M, Hui AM, Tsurumaru M and Nagase H: Frequent trefoil factor 3 (TFF3) overexpression and promoter hypomethylation in mouse and human hepatocellular carcinomas. Int J Oncol. 26:369–377. 2005.PubMed/NCBI

44 

Vestergaard EM, Nexø E, Tørring N, Borre M, Ørntoft TF and Sørensen KD: Promoter hypomethylation and upregulation of trefoil factorsin prostate cancer. Int J Cancer. 127:1857–1865. 2010. View Article : Google Scholar : PubMed/NCBI

45 

Ribieras S, Lefèbvre O, Tomasetto C and Rio MC: Mouse Trefoil factor genes: Genomic organization, sequences and methylation analyses. Gene. 266:67–75. 2001. View Article : Google Scholar : PubMed/NCBI

46 

Sato N, Maitra A, Fukushima N, van Heek NT, Matsubayashi H, Iacobuzio-Donahue CA, Rosty C and Goggins M: Frequent hypomethylation of multiple genes overexpressed in pancreatic ductal adenocarcinoma. Cancer Res. 63:4158–4166. 2003.PubMed/NCBI

47 

Zheng Q, Gao J, Li H, Guo W, Mao Q, Gao E and Zhu YQ: Trefoil factor 3 peptide regulates migration via a Twist-dependent pathway in gastric cell. Biochem Biophys Res Commun. 438:6–12. 2013. View Article : Google Scholar : PubMed/NCBI

48 

Uchino H, Kataoka H, Itoh H, Sekiya R, Onitsuka T and Koono M: Roles of intestinal trefoil factor (ITF) in human colorectal cancer: ITF suppresses the growth of colorectal carcinoma cells. Hum Cell. 12:181–188. 1999.

49 

Uchino H, Kataoka H, Itoh H, Hamasuna R and Koono M: Overexpression of intestinal trefoil factor in human colon carcinoma cells reduces cellular growth in vitro and in vivo. Gastroenterology. 118:60–69. 2000. View Article : Google Scholar

50 

Chan VY, Chan MW, Leung WK, Leung PS, Sung JJ and Chan FK: Intestinal trefoil factor promotes invasion in non-tumorigenic Rat-2 fibroblast cell. Regul Pept. 127:87–94. 2005. View Article : Google Scholar : PubMed/NCBI

51 

Lin J, Sun Z, Zhang W, Liu H, Shao D, Ren Y, Wen Y, Cao L, Wolfram J, Yang Z, et al: Protective effects of intestinal trefoil factor (ITF) on gastric mucosal epithelium through activation of extracellular signal regulated kinase 1/2 (ERK1/2). Mol Cell Biochem. 404:263–270. 2015. View Article : Google Scholar : PubMed/NCBI

52 

Perera O, Evans A, Pertziger M, MacDonald C, Chen H, Liu DX, Lobie PE and Perry JK: Trefoil factor 3 (TFF3) enhances the oncogenic characteristics of prostate carcinoma cells and reduces sensitivity to ionising radiation. Cancer Lett. 361:104–111. 2015. View Article : Google Scholar : PubMed/NCBI

53 

Liu J, Kim SY, Shin S, Jung SH, Yim SH, Lee JY, Lee SH and Chung YJ: Overexpression of TFF3 is involved in prostate carcinogenesis via blocking mitochondria-mediated apoptosis. Exp Mol Med. 50:110–117. 2018. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

October 2019
Volume 55 Issue 4

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Yusufu, A., Shayimu, P., Tuerdi, R., Fang, C., Wang, F., & Wang, H. (2019). TFF3 and TFF1 expression levels are elevated in colorectal cancer and promote the malignant behavior of colon cancer by activating the EMT process. International Journal of Oncology, 55, 789-804. https://doi.org/10.3892/ijo.2019.4854
MLA
Yusufu, A., Shayimu, P., Tuerdi, R., Fang, C., Wang, F., Wang, H."TFF3 and TFF1 expression levels are elevated in colorectal cancer and promote the malignant behavior of colon cancer by activating the EMT process". International Journal of Oncology 55.4 (2019): 789-804.
Chicago
Yusufu, A., Shayimu, P., Tuerdi, R., Fang, C., Wang, F., Wang, H."TFF3 and TFF1 expression levels are elevated in colorectal cancer and promote the malignant behavior of colon cancer by activating the EMT process". International Journal of Oncology 55, no. 4 (2019): 789-804. https://doi.org/10.3892/ijo.2019.4854